SCHEMBL1720739

SCHEMBL1720739

CCc1[nH]c(=O)c2cc(F)ccc2c1CN1CCC[C@H]1CO

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.43
CFB P00751 1/20 0.41
SPHK1 Q9NYA1 7/20 0.41
SPHK2 Q9NRA0 6/20 0.41
DDR1 Q08345 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
PNP P00491 2/20 0.37
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CDC7 O00311 2/20 0.36
CCNE1 P24864 2/20 0.36
CDK2 P24941 2/20 0.36
ROCK1 Q13464 2/20 0.36
DBF4 Q9UBU7 2/20 0.36
DPP4 P27487 1/20 0.36
DPP8 Q6V1X1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1720556 1.00 PARP1 (0.43) PARP1CFBSPHK1SPHK2DDR1
SCHEMBL1720740 1.00 PARP1 (0.43) PARP1CFBSPHK1SPHK2DDR1
SCHEMBL1719877 0.88 DDR1 (0.45) PARP1CFBSPHK1SPHK2DDR1
SCHEMBL1719879 0.88 DDR1 (0.45) PARP1CFBSPHK1SPHK2DDR1
SCHEMBL1720592 0.88 DDR1 (0.45) PARP1CFBSPHK1SPHK2DDR1
SCHEMBL1720897 0.88 PARP1 (0.47) PARP1CFBSPHK1SPHK2DDR1
SCHEMBL1719667 0.88 PARP1 (0.47) PARP1CFBSPHK1SPHK2DDR1
SCHEMBL1719665 0.88 PARP1 (0.47) PARP1CFBSPHK1SPHK2DDR1
SCHEMBL1720371 0.86 PARP1 (0.52) PARP1CFBSPHK1SPHK2MEN1
SCHEMBL1721092 0.86 PARP1 (0.52) PARP1CFBSPHK1SPHK2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US claimed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US claimed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP claimed
EP-1566380-B1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-01-11 EP disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 PARP1 1/4885CFB 3353/4885SPHK1 1422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.